Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2008

View Archived Issues

Ghrelin involved in mood responses to stress

Tezampanel is safe and effectively treats acute migraine in a phase IIb study

RegeneRx completes enrollment and dosing in phase Ia safety trial for RGN-352

CardioMetabolics announces name change to Valens Pharma

Initial phase II ASI-1411 findings show promise in acute myeloid leukemia

pSivida commences BrachySil phase IIb pancreatic cancer trial

APP to be acquired by Fresenius

Wilex completes patient recruitment in phase III ARISER trial of Rencarex in clear cell RCC

Senetek terminates Invicorp license agreement with Ardana

Medicago receives funding for the development of VLP flu vaccine

New treatments for neurological disorders reported in recent patent literature

Novel anticancer agents disclosed in recent patents

Selective androgen receptor modulator-like properties seen with MK-0773

ARD-07 bioavailability reduced by food

Encouraging results seen with Chronocort in congenital adrenal hyperplasia

Almirall and Forest Laboratories complete phase III ACCLAIM/COPD studies

ARC-1779 gains orphan designation for thrombotic thrombocytopenic purpura

ImmunoGen initiates patient dosing in IMGN-388 trial in solid tumors

Labopharm reaquires U.K. sales and marketing rights to tramadol

ImmuPharma reports results from 6-month toxicology study of Lupuzor for lupus

Tripep submits new application to Medical Products Agency for phase II study of ChronSeal

ImClone initiates enrollment in phase II clinical trial of IMC-A12 in soft tissue sarcoma

Recent Allergan patent describes novel agents for glaucoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...